Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 160 of the 163 references it cites were found in a registry or an index.

Current challenges in biotherapeutic particles manufacturing

Open access

Abstract

Introduction: The development of novel complex biotherapeutics led to new challenges in biopharmaceutical industry. The potential of these particles has been demonstrated by the approval of several products, in the different fields of gene therapy, oncolytic therapy, and tumor vaccines. However, their manufacturing still presents challenges related to the high dosages and purity required.Areas covered: The main challenges that biopharmaceutical industry faces today and the most recent developments in the manufacturing of different biotherapeutic particles are reported here. Several unit operations and downstream trains to purify virus, virus-like particles and extracellular vesicles are described. Innovations on the different purification steps are also highlighted with an eye on the implementation of continuous and integrated processes.Expert opinion: Manufacturing platforms that consist of a low number of unit operations, with higher-yielding processes and reduced costs will be highly appreciated by the industry. The pipeline of complex therapeutic particles is expanding and there is a clear need for advanced tools and manufacturing capacity. The use of single-use technologies, as well as continuous integrated operations, are gaining ground in the biopharmaceutical industry and should be supported by more accurate and faster analytical methods.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1080/14712598.2020.1693541

Cites

160 of 160 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 163 references

Research works printed but not linked: 18

  1. Reiter M, 2005, Method for large scale production of virus antigen
  2. Kamilla S, Virgínia PC. Recombinant Glycoprotein Production: Methods and Protocols. New York: Springer; 2018.
  3. Reimer CB, 1966, Am Assoc Adv Sci, 152, 1379
  4. Morita M, 2011, Hitachi Rev, 60, 257
  5. Xenopoulos A, 2015, EMD Millipore Webinar Ser
  6. Iammarino M, 2007, Bioprocess Int, 38
  7. Gousseinov E, 2014, Bioprocess Int, 12, 59
  8. Oxford Biomedica plc. SecNunc™ for AAVs, lentiviral vectors and adenovirus (Application Note), 2019, p. 1–2.
  9. Healthcare GE, 2014, Concentration and diafiltration of cell-derived, live influenza virus using 750 C hollow fiber filter cartridge (Application note 29-0928-26 AA)
  10. Mietzsch M, 2015, Human., 12
  11. Hansen SP, 2015, Purification of vaccinia viruses using hydrophobic interaction chromatography
  12. Gagnon P, 2009, Encycl Ind Biotechnol
  13. Gagnon P, 2008, BioProcess Int
  14. Lima TM, 2019, Vaccine., 1
  15. Shin H, 2018, PLoS One, 13, 1
  16. Jagschies G, 2018, Biopharmaceutical processing - development, design, and implementation of manufacturing processes
  17. Yang L, 2016, Front Microbiol, 7
  18. Kingstad-Bakke BA, 2018, Zika virus vaccines using virus-like particles

Cited by

See all 123

Metadata

Authors
Moleirinho, M. G., Silva, R. J. S., Alves, P. M., Carrondo, M. J. T., & Peixoto, C.
Affiliations
Instituto de Biologia Experimental e Tecnológica (PT)
Corresponding author
Peixoto, Cristina
Venue
Expert Opinion on Biological Therapy
Published
2019-11-27
Volume
20
Issue
5
Pages
451-465
ISSN
  • 1471-2598 (ISSN-L)
  • 1744-7682
OpenAlex
W2990128831
Cited by
123
References
163
Citations by year
2026: 10 · 2025: 21 · 2024: 23 · 2023: 18 · 2022: 21 · 2021: 20 · 2020: 9
FWCI
1.10
Type
journal article
Language
en
Open access
Locations
  • Expert Opinion on Biological Therapy (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein purification and stability
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Viral Infectious Diseases and Gene Expression in Insects
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
Keywords
production problems, virus-like particles, extracellular vesicles, gene therapy, oncolytic virotherapy, cancer vaccines, downstream purification, continuous production, single-use technology, analytical methods
MeSH terms
Extracellular Vesicles, Antibodies, Monoclonal, Biological Products, Drug Industry, Viruses, Vaccines, Virus-Like Particle

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Current challenges in biotherapeutic particles manufacturing. https://app.cochat.ai/papers/10.1080/14712598.2020.1693541
The paper
Moleirinho, M. G., Silva, R. J. S., Alves, P. M., Carrondo, M. J. T., & Peixoto, C. (2020). Current challenges in biotherapeutic particles manufacturing. Expert Opinion on Biological Therapy. https://doi.org/10.1080/14712598.2020.1693541

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.